Copart Director Daniel Englander: Insider Sale Impact on CPRT
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
Overview of beginner-friendly HYSA options, focusing on accessibility, straightforward terms, and competitive rates.
24,631 articlesCopart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
Global dividend payments in Q3 2025 surged to a record, signaling the largest dividend payout history and fueling ren...
One staffing stock plunged 56% in the last year, but a large new stake worth almost $10 million could signal a forthc...
The AI boom isn’t just about memory chips anymore. A broader wave of demand is lifting compute, software, and data in...
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
A historically cheap, safe stock is gaining attention as investors seek stability in an expensive market. NextEra Ene...
A clear look at how Vanguard Health Care and iShares Biotechnology compete for space in a diversified portfolio. Lear...
As lawmakers wrangle over the CLARITY Act, one name stands out for cautious investors: Bitcoin. This guide explains w...
On Feb 26, The Trade Desk faced a sharp move as management guided softer revenue growth and rising margins strained b...
Micron Technology posted strong results, yet the stock slipped. This guide weighs whether micron's dip: great chance ...
This article breaks down what to watch in enovix (envx) 2026 earnings, translating management comments into actionabl...
Progressive and Lemonade sit at opposite ends of the insurance spectrum in 2026. This guide breaks down their models,...